{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:00:54Z","timestamp":1784041254016,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1 TR002556"],"award-info":[{"award-number":["UL1 TR002556"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K23DA055933"],"award-info":[{"award-number":["K23DA055933"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R34DA039041"],"award-info":[{"award-number":["R34DA039041"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Buprenorphine (BUP) treatment has been successfully integrated into primary care and other general medical settings; however, potential BUP prescribers frequently report inadequate training and resources to provide psychosocial counseling as barriers to providing care. Group medical visits, which combine psychosocial support and chronic condition management, have been described for BUP treatment, but few studies have explored what is gained and\/or lost by offering BUP treatment in groups instead of individual visits.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Five focus groups with 3\u201311 participants each were conducted at an urban community health center that housed a mature office-based BUP treatment program. Participants were persons with opioid use disorder (OUD) who had previously received BUP treatment. A semi-structured interview guide covered the following domains: experience with BUP, experience with group counseling, and preferences for BUP in a group format or individual setting. Qualitative analysis followed a modified grounded theory approach.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of 33 participants, 28 were male, median age range was 50\u201354, 20 identified as Hispanic\/Latinx, and 24 reported past experiences with substance use disorder treatment groups. Four main themes were: (1) Groups can address the psychological aspects of addiction; (2) Groups introduce positive peer support; (3) Balancing OUD treatment and management of other chronic conditions; (4) Groups must be voluntary.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Findings demonstrate that many persons with OUD taking BUP desire assistance with recovery skills, peer support, and learning about the risks and benefits of BUP. Group medical visits can efficiently deliver these services in primary care, but findings also emphasize that group counseling will be best received when voluntary and group members are committed and authentic.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13722-025-00540-7","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T10:34:46Z","timestamp":1738751686000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["\u201cThere\u2019s always somebody that you can identify with\u201d: a qualitative study of patient perspectives on buprenorphine group medical visits"],"prefix":"10.1186","volume":"20","author":[{"given":"Mariya","family":"Masyukova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin T.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"L\u00f3pez-Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron D.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"issue":"Suppl 1","key":"540_CR1","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1097\/QAI.0b013e31820a8226","volume":"56","author":"L Weiss","year":"2011","unstructured":"Weiss L, Netherland J, Egan JE, Flanigan TP, Fiellin DA, Finkelstein R, et al. Integration of buprenorphine\/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S68\u201375.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7","key":"540_CR2","first-page":"500","volume":"40","author":"C Cunningham","year":"2008","unstructured":"Cunningham C, Giovanniello A, Sacajiu G, Whitley S, Mund P, Beil R, et al. Buprenorphine treatment in an urban community health center: what to expect. Fam Med. 2008;40(7):500\u20136.","journal-title":"Fam Med"},{"key":"540_CR3","doi-asserted-by":"crossref","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2:CD002207.","DOI":"10.1002\/14651858.CD002207.pub4"},{"issue":"2","key":"540_CR4","doi-asserted-by":"publisher","first-page":"e1920622","DOI":"10.1001\/jamanetworkopen.2019.20622","volume":"3","author":"SE Wakeman","year":"2020","unstructured":"Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, et al. Comparative effectiveness of different treatment pathways for opioid Use Disorder. JAMA Netw Open. 2020;3(2):e1920622.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"540_CR5","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1056\/NEJMoa055255","volume":"355","author":"DA Fiellin","year":"2006","unstructured":"Fiellin DA, Pantalon MV, Chawarski MC, Moore BA, Sullivan LE, O\u2019Connor PG, et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med. 2006;355(4):365\u201374.","journal-title":"N Engl J Med"},{"issue":"Suppl 1Suppl 1","key":"540_CR6","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1097\/QAI.0b013e318209754c","volume":"56","author":"PT Korthuis","year":"2011","unstructured":"Korthuis PT, Tozzi MJ, Nandi V, Fiellin DA, Weiss L, Egan JE, et al. Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics. J Acquir Immune Defic Syndr. 2011;56(Suppl 1Suppl 1):S39\u201345.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"540_CR7","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.jsat.2008.06.006","volume":"36","author":"J Netherland","year":"2009","unstructured":"Netherland J, Botsko M, Egan JE, Saxon AJ, Cunningham CO, Finkelstein R, et al. Factors affecting willingness to provide buprenorphine treatment. J Subst Abuse Treat. 2009;36(3):244\u201351.","journal-title":"J Subst Abuse Treat"},{"key":"540_CR8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.addbeh.2019.01.023","volume":"93","author":"LA Lin","year":"2019","unstructured":"Lin LA, Lofwall MR, Walsh SL, Knudsen HK. Perceived need and availability of psychosocial interventions across buprenorphine prescriber specialties. Addict Behav. 2019;93:72\u20137.","journal-title":"Addict Behav"},{"issue":"1","key":"540_CR9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1080\/08897077.2015.1088496","volume":"37","author":"AD Fox","year":"2016","unstructured":"Fox AD, Masyukova M, Cunningham CO. Optimizing psychosocial support during office-based buprenorphine treatment in primary care: patients\u2019 experiences and preferences. Subst Abus. 2016;37(1):70\u20135.","journal-title":"Subst Abus"},{"issue":"2","key":"540_CR10","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1080\/10826084.2017.1385633","volume":"53","author":"AE Hatcher","year":"2018","unstructured":"Hatcher AE, Mendoza S, Hansen H. At the expense of a life: race, Class, and the meaning of Buprenorphine in Pharmaceuticalized Care. Subst Use Misuse. 2018;53(2):301\u201310.","journal-title":"Subst Use Misuse"},{"issue":"15","key":"540_CR11","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1001\/jama.1993.03500150065028","volume":"269","author":"AT McLellan","year":"1993","unstructured":"McLellan AT, Arndt IO, Metzger DS, Woody GE, O\u2019Brien CP. The effects of psychosocial services in substance abuse treatment. JAMA. 1993;269(15):1953\u20139.","journal-title":"JAMA"},{"issue":"1","key":"540_CR12","doi-asserted-by":"publisher","first-page":"e7411","DOI":"10.1016\/j.amjmed.2012.07.005","volume":"126","author":"DA Fiellin","year":"2013","unstructured":"Fiellin DA, Barry DT, Sullivan LE, Cutter CJ, Moore BA, O\u2019Connor PG, et al. A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. Am J Med. 2013;126(1):e7411\u20137.","journal-title":"Am J Med"},{"issue":"10","key":"540_CR13","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1111\/add.12266","volume":"108","author":"W Ling","year":"2013","unstructured":"Ling W, Hillhouse M, Ang A, Jenkins J, Fahey J. Comparison of behavioral treatment conditions in buprenorphine maintenance. Addiction. 2013;108(10):1788\u201398.","journal-title":"Addiction"},{"issue":"4","key":"540_CR14","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jsat.2012.07.011","volume":"43","author":"JM Tetrault","year":"2012","unstructured":"Tetrault JM, Moore BA, Barry DT, O\u2019Connor PG, Schottenfeld R, Fiellin DA, et al. Brief versus extended counseling along with buprenorphine\/naloxone for HIV-infected opioid dependent patients. J Subst Abuse Treat. 2012;43(4):433\u20139.","journal-title":"J Subst Abuse Treat"},{"issue":"12","key":"540_CR15","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1001\/archgenpsychiatry.2011.121","volume":"68","author":"RD Weiss","year":"2011","unstructured":"Weiss RD, Potter JS, Fiellin DA, Byrne M, Connery HS, Dickinson W, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry. 2011;68(12):1238\u201346.","journal-title":"Arch Gen Psychiatry"},{"key":"540_CR16","doi-asserted-by":"publisher","first-page":"108923","DOI":"10.1016\/j.drugalcdep.2021.108923","volume":"228","author":"JJ Wyse","year":"2021","unstructured":"Wyse JJ, Morasco BJ, Dougherty J, Edwards B, Kansagara D, Gordon AJ, et al. Adjunct interventions to standard medical management of buprenorphine in outpatient settings: a systematic review of the evidence. Drug Alcohol Depend. 2021;228:108923.","journal-title":"Drug Alcohol Depend"},{"key":"540_CR17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jsat.2015.05.005","volume":"57","author":"LB Monico","year":"2015","unstructured":"Monico LB, Gryczynski J, Mitchell SG, Schwartz RP, O\u2019Grady KE, Jaffe JH. Buprenorphine Treatment and 12-step meeting attendance: conflicts, compatibilities, and patient outcomes. J Subst Abuse Treat. 2015;57:89\u201395.","journal-title":"J Subst Abuse Treat"},{"key":"540_CR18","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.drugalcdep.2014.04.005","volume":"140","author":"RD Weiss","year":"2014","unstructured":"Weiss RD, Griffin ML, Potter JS, Dodd DR, Dreifuss JA, Connery HS, et al. Who benefits from additional drug counseling among prescription opioid-dependent patients receiving buprenorphine-naloxone and standard medical management? Drug Alcohol Depend. 2014;140:118\u201322.","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"540_CR19","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/ADM.0000000000000071","volume":"8","author":"R Berger","year":"2014","unstructured":"Berger R, Pulido C, Lacro J, Groban S, Robinson S. Group medication management for buprenorphine\/naloxone in opioid-dependent veterans. J Addict Med. 2014;8(6):415\u201320.","journal-title":"J Addict Med"},{"issue":"2","key":"540_CR20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1080\/08897077.2014.998400","volume":"36","author":"J Suzuki","year":"2015","unstructured":"Suzuki J, Zinser J, Klaiber B, Hannon M, Grassi H, Spinosa M, et al. Feasibility of implementing Shared Medical appointments (SMAs) for Office-based opioid treatment with buprenorphine: a pilot study. Subst Abus. 2015;36(2):166\u20139.","journal-title":"Subst Abus"},{"issue":"1","key":"540_CR21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1080\/08897077.2016.1264535","volume":"38","author":"SL Doorley","year":"2017","unstructured":"Doorley SL, Ho CJ, Echeverria E, Preston C, Ngo H, Kamal A, et al. Buprenorphine shared medical appointments for the treatment of opioid dependence in a homeless clinic. Subst Abus. 2017;38(1):26\u201330.","journal-title":"Subst Abus"},{"issue":"5","key":"540_CR22","doi-asserted-by":"publisher","first-page":"676","DOI":"10.3122\/jabfm.2015.05.150017","volume":"28","author":"D Roll","year":"2015","unstructured":"Roll D, Spottswood M, Huang H. Using Shared Medical appointments to increase Access to Buprenorphine Treatment. J Am Board Fam Med. 2015;28(5):676\u20137.","journal-title":"J Am Board Fam Med"},{"key":"540_CR23","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jsat.2017.11.003","volume":"84","author":"R Sokol","year":"2018","unstructured":"Sokol R, LaVertu AE, Morrill D, Albanese C, Schuman-Olivier Z. Group-based treatment of opioid use disorder with buprenorphine: a systematic review. J Subst Abuse Treat. 2018;84:78\u201387.","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"540_CR24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13722-019-0176-y","volume":"14","author":"R Sokol","year":"2019","unstructured":"Sokol R, Albanese M, Chew A, Early J, Grossman E, Roll D, et al. Building a Group-based opioid treatment (GBOT) blueprint: a qualitative study delineating GBOT implementation. Addict Sci Clin Pract. 2019;14(1):47.","journal-title":"Addict Sci Clin Pract"},{"issue":"1","key":"540_CR25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1377\/hlthaff.2011.0913","volume":"31","author":"RE Burke","year":"2012","unstructured":"Burke RE, O\u2019Grady ET. Group visits hold great potential for improving diabetes care and outcomes, but best practices must be developed. Health Aff (Millwood). 2012;31(1):103\u20139.","journal-title":"Health Aff (Millwood)"},{"issue":"5","key":"540_CR26","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1136\/qshc.2006.019158","volume":"16","author":"S Kirsh","year":"2007","unstructured":"Kirsh S, Watts S, Pascuzzi K, O\u2019Day ME, Davidson D, Strauss G, et al. Shared medical appointments based on the chronic care model: a quality improvement project to address the challenges of patients with diabetes with high cardiovascular risk. Qual Saf Health Care. 2007;16(5):349\u201353.","journal-title":"Qual Saf Health Care"},{"issue":"9","key":"540_CR27","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s00125-002-0904-8","volume":"45","author":"M Trento","year":"2002","unstructured":"Trento M, Passera P, Bajardi M, Tomalino M, Grassi G, Borgo E, et al. Lifestyle intervention by group care prevents deterioration of type II diabetes: a 4-year randomized controlled clinical trial. Diabetologia. 2002;45(9):1231\u20139.","journal-title":"Diabetologia"},{"issue":"12","key":"540_CR28","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.2337\/diacare.22.12.2011","volume":"22","author":"CN Sadur","year":"1999","unstructured":"Sadur CN, Moline N, Costa M, Michalik D, Mendlowitz D, Roller S, et al. Diabetes management in a health maintenance organization. Efficacy of care management using cluster visits. Diabetes Care. 1999;22(12):2011\u20137.","journal-title":"Diabetes Care"},{"key":"540_CR29","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/1472-6963-13-155","volume":"13","author":"JG Lavoie","year":"2013","unstructured":"Lavoie JG, Wong ST, Chongo M, Browne AJ, MacLeod ML, Ulrich C. Group medical visits can deliver on patient-centred care objectives: results from a qualitative study. BMC Health Serv Res. 2013;13:155.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"540_CR30","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/08897077.2017.1356792","volume":"39","author":"R Sokol","year":"2018","unstructured":"Sokol R, Albanese C, Chaponis D, Early J, Maxted G, Morrill D, et al. Why use group visits for opioid use disorder treatment in primary care? A patient-centered qualitative study. Subst Abus. 2018;39(1):52\u20138.","journal-title":"Subst Abus"},{"issue":"6","key":"540_CR31","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349\u201357.","journal-title":"Int J Qual Health Care"},{"issue":"2","key":"540_CR32","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1037\/0022-0167.52.2.126","volume":"52","author":"JG Ponterotto","year":"2005","unstructured":"Ponterotto JG. Qualitative research in counseling psychology: a primer on research paradigms and philosophy of science. J Couns Psychol. 2005;52(2):126\u201336.","journal-title":"J Couns Psychol"},{"key":"540_CR33","unstructured":"Auerbach C, Silverstein LB. Qualitative data: an introduction to Coding and Analysis. NYU. 2003."},{"issue":"Suppl 1","key":"540_CR34","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1097\/QAI.0b013e318209751e","volume":"56","author":"FL Altice","year":"2011","unstructured":"Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthuis PT, Flanigan TP, et al. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine\/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S22\u201332.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2\u20133","key":"540_CR35","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.drugalcdep.2006.10.010","volume":"88","author":"RH Moos","year":"2007","unstructured":"Moos RH. Theory-based active ingredients of effective treatments for substance use disorders. Drug Alcohol Depend. 2007;88(2\u20133):109\u201321.","journal-title":"Drug Alcohol Depend"},{"key":"540_CR36","unstructured":"Burlingame GM, Strauss B, Joyce AS. Change mechanisms and effectiveness of small group treatments. In: Lambert MJ, editor. Bergin and Garfield\u2019s handbook of psychotherapy and behavior change. 6th ed. Wiley 2013;640\u201389."},{"key":"540_CR37","volume-title":"Substance abuse treatment: Group Therapy. Treatment improvement protocol (TIP) series, No. 41. HHS Publication No. (SMA) 15-3991","author":"Center for Substance Abuse Treatment","year":"2005","unstructured":"Center for Substance Abuse Treatment. Substance abuse treatment: Group Therapy. Treatment improvement protocol (TIP) series, No. 41. HHS Publication No. (SMA) 15-3991. Rockville, MD: Substance Abuse and Mental Health Services Administration. 2005."},{"issue":"5","key":"540_CR38","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1176\/ajp.137.5.535","volume":"137","author":"GL Engel","year":"1980","unstructured":"Engel GL. The clinical application of the biopsychosocial model. Am J Psychiatry. 1980;137(5):535\u201344.","journal-title":"Am J Psychiatry"},{"issue":"9","key":"540_CR39","doi-asserted-by":"publisher","first-page":"628","DOI":"10.7326\/M18-1652","volume":"169","author":"SA Martin","year":"2018","unstructured":"Martin SA, Chiodo LM, Bosse JD, Wilson A. The next stage of Buprenorphine Care for Opioid Use Disorder. Ann Intern Med. 2018;169(9):628\u201335.","journal-title":"Ann Intern Med"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00540-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-025-00540-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00540-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T10:34:52Z","timestamp":1738751692000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-025-00540-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["540"],"URL":"https:\/\/doi.org\/10.1186\/s13722-025-00540-7","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,5]]},"assertion":[{"value":"9 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Albert Einstein College of Medicine Institutional Review Board approved of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}